291 related articles for article (PubMed ID: 11479257)
1. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Lele M; Sajid M; Wajih N; Stouffer GA
Circulation; 2001 Jul; 104(5):582-7. PubMed ID: 11479257
[TBL] [Abstract][Full Text] [Related]
2. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Scarborough RM
Circulation; 2002 Feb; 105(6):e46. PubMed ID: 11839641
[No Abstract] [Full Text] [Related]
3. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
Tam SH; Sassoli PM; Jordan RE; Nakada MT
Circulation; 1998 Sep; 98(11):1085-91. PubMed ID: 9736595
[TBL] [Abstract][Full Text] [Related]
4. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
5. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells.
Stouffer GA; Hu Z; Sajid M; Li H; Jin G; Nakada MT; Hanson SR; Runge MS
Circulation; 1998 Mar; 97(9):907-15. PubMed ID: 9521340
[TBL] [Abstract][Full Text] [Related]
6. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
7. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
[TBL] [Abstract][Full Text] [Related]
8. Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells.
Kintscher U; Kappert K; Schmidt G; Doerr G; Grill M; Wollert-Wulf B; Graefe M; Fleck E; Graf K
Eur J Pharmacol; 2000 Feb; 390(1-2):75-87. PubMed ID: 10708709
[TBL] [Abstract][Full Text] [Related]
9. Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells.
Pathak A; Zhao R; Huang J; Stouffer GA
Cardiovasc Diabetol; 2008 Dec; 7():36. PubMed ID: 19108709
[TBL] [Abstract][Full Text] [Related]
10. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
[TBL] [Abstract][Full Text] [Related]
11. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Moser M; Bertram U; Peter K; Bode C; Ruef J
J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
[TBL] [Abstract][Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
13. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis.
Yeh CH; Peng HC; Huang TF
Blood; 1998 Nov; 92(9):3268-76. PubMed ID: 9787163
[TBL] [Abstract][Full Text] [Related]
14. Decrease of vascular smooth muscle cell locomotion by abciximab, but not tirofiban: a possible role of different affinity to alpha v beta 3 integrins.
Blindt R; Bosserhoff AK; Krott N; Vogt F; Hanrath P; Demircan L; vom Dahl J
Coron Artery Dis; 2002 Nov; 13(7):357-64. PubMed ID: 12488644
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Lisman T; Moschatsis S; Adelmeijer J; Nieuwenhuis HK; De Groot PG
Blood; 2003 Mar; 101(5):1864-70. PubMed ID: 12411291
[TBL] [Abstract][Full Text] [Related]
19. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
